(XBI)

AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.

The Federal Reserve's inflation battle appears to be ending, and investors who position themselves correctly could capture significant gains. Producer prices unexpectedly dropped in August, while the ...

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched ...

XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA...